Journal Article Review Research Support, Non-U.S. Gov't Ppublish 2 citations
PubMed: 39501551 DOI: 10.1080/21505594.2024.2425773
Adjuvants for vaccines: Outer membrane vesicles provide an alternative strategy.
Virulence 15(1):2425773
Authors: Hanchi Zhang, Zhili Liu, Yi Li, Ziwei Tao, Lu Shen, Yinpan Shang, Xiaotian Huang, Qiong Liu
Affiliations
- Department of Medical Microbiology, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, China. The Second Clinical Medical College, Nanchang University, Nanchang, China.
- Department of Medical Microbiology, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, China.
- Department of Medical Microbiology, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, China. The First Clinical Medical College, Nanchang University, Nanchang, China.
Abstract
() is a gram-negative, spiral-shaped bacterium that colonizes the human stomach, leading to various gastric diseases. The efficacy of traditional treatments, such as bismuth-based triple and quadruple therapies, has been reduced due to increasing antibiotic resistance and drug toxicity. As a result, the development of effective vaccines was proposed to control -induced infections; however, one of the primary challenges is the lack of potent adjuvants. Although various adjuvants, both toxic (e.g. cholera toxin and heat-labile toxin) and non-toxic (e.g. aluminum and propolis), have been tested for vaccine development, no clinically favorable adjuvants have been identified due to high toxicity, weak immunostimulatory effects, inability to elicit specific immune responses, or latent side effects. Outer membrane vesicles (OMVs), mainly secreted by gram-negative bacteria, have emerged as promising candidates for vaccine adjuvants due to their potential applications. OMVs enhance mucosal immunity and Th1 and Th17 cell responses, which have been recognized to have protective effects and guarantee safety and efficacy. The development of an effective vaccine against infection is ongoing, with clinical trials expected in the future.
MeSH
Vaccines, Immunity, Therapeutics, Virulence, Membranes, Infections
Cited by
- Development of a Recombinant Outer Membrane Vesicles (OMVs)-Based Vaccine Against Helicobacter pylori Infection in Mice. J Extracell Vesicles, 2025
- Helicobacter pylori Vaccine: Mechanism of Pathogenesis, Immune Evasion and Analysis of Vaccine Types. Vaccines (Basel), 2025
- infection process: from the molecular world to clinical treatment. Front Microbiol, 2025